Introduction {#Sec1}
============

Atopic dermatitis (AD) is the most common inflammatory skin disease of childhood, affecting about 20% of children \[[@CR1]\]. AD usually resolves before adolescence. However, it sometimes persists in adulthood (persistent AD), and in some cases the disease starts in adulthood (adult-onset AD) \[[@CR2]\]. It is reported that the prevalence of childhood AD is steadily increasing, especially in industrialized countries \[[@CR3]\]. In the same way, it is likely that the frequency of the adult form has also been increasing in recent years, as even reported for elderly patients \[[@CR4]\]. Current prevalence data regarding adult AD are very variable, with values ranging from 0.3 to 14.3%, even though most authors agree that AD affects 1--3% of adults \[[@CR5]\]. AD has a chronic relapsing course and significantly affects the quality of life of patients, especially adults with severe and long-lasting AD \[[@CR6]\]. The diagnosis of adult AD is usually clinical, since traditional diagnostic criteria used for children are not always applicable to adults \[[@CR5]\]. Studies are now underway that aim to better define the clinical characteristics of the disease \[[@CR7], [@CR8]\]. In mild cases, topical treatment includes corticosteroids and calcineurin inhibitors in addition to emollient agents, which are the cornerstone of treatment in all cases of AD \[[@CR1]\]. Adjunctive systemic treatment is needed in moderate-to-severe cases \[[@CR9]\]. Phototherapy, cyclosporine A (CsA), methotrexate, and azathioprine are the main immunosuppressors used in AD treatment, while corticosteroids are used only for acute exacerbations \[[@CR1]\]. Currently, cyclosporine is the only labeled medicament available for the treatment of AD. Due to the chronicity of the condition, long-term immunosuppressive treatment is often required. Subsequently, continuous follow-up is needed, as all of the abovementioned drugs may have important side effects \[[@CR9]\]. Moreover, these therapies show different efficacies \[[@CR9]\]. In recent years, several studies have elucidated the pathogenesis of the disease, especially as regards the roles of some cytokines \[[@CR10]\]. This has led to the introduction of new drugs targeting individual cells or a mediator of the inflammatory response \[[@CR1], [@CR9]\]. Among these new drugs, biologic agents are playing a leading role. Currently, the monoclonal antibody dupilumab is the only biologic drug licensed for the treatment of AD in adults \[[@CR1], [@CR7]\]. Dupilumab blocks interleukin (IL)-4 and IL-13, two cytokines that play a key role in the development of type 2 helper (Th2) lymphocyte-mediated skin inflammation in AD \[[@CR11]\]. Other biologic medicaments---drugs that selectively inhibit some cytokines (namely IL-13, IL-31, and IL-22) that play prominent roles in the pathogenesis of DA---are also under investigation \[[@CR1]\].

This review summarizes currently available biologic therapies for adult AD based on an analysis of the literature in this field, and highlights possible future scenarios for this kind of treatment.

Methods {#Sec2}
=======

For the current review, relevant literature published in English was searched for. The studies we selected concerned systemic biologic therapy of adult atopic dermatitis. We selected controlled phase II and III trials as well as reviews, guidelines, and consensus. Research was carried out by searching the following databases through to June 30, 2018: PubMed, Embase, The Cochrane Library, Google Scholar, EBSCO, and clinicaltrials.gov. The following keywords were used: "atopic dermatitis," "atopic eczema," "adult atopic dermatitis," "adult atopic eczema," "systemic treatment," "systemic therapy," "biologics," "monoclonal antibody," "IL-4 monoclonal antibody," "IL-13 monoclonal antibody," "IL-31 monoclonal antibody," and "IL-22 monoclonal antibody." This article is based on previously conducted studies and does not involve any new study of human or animal subjects performed by any of the authors.

Biologic Drugs {#Sec3}
==============

The development of biological therapies has progressed rapidly in the last few years. Biologic drugs are a class of pharmacological agents that are engineered to target specific mediators of inflammation. Recently, multiple clinical trials have demonstrated the efficacy of targeted therapy involving the blocking of cytokines or mediators that play a pivotal role in the pathogenesis of AD. Dupilumab is currently the only biologic drug that has been approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of adult patients with inadequately controlled moderate-to-severe AD \[[@CR12]\]. Biological drugs appear to be promising treatments for adult AD patients because they offer more convenient dose regimens and allow less frequent laboratory monitoring than other systemic therapies, as well as having fewer side effects \[[@CR1]\]. Future studies are needed to fulfill unmet needs and achieve better standards of care for AD patients, to clarify the roles of other biologic drugs under investigation for AD therapy, and to completely revolutionize adult AD treatment.

IL-4 and/or IL-13 Inhibitors {#Sec4}
----------------------------

*Dupilumab* is a fully human monoclonal antibody that binds to the shared alpha chain subunit of the receptors for IL-4 and IL-13 \[[@CR13]\]. This results in downregulation of receptor signaling downstream of the JAK/STAT pathway, which regulates the expression of many genes involved in the pathogenesis of AD \[[@CR14]\]. In March 2017, dupilumab received its first national approval, from the USA, for its use in the treatment of adult patients with moderate-to-severe AD whose disease is not adequately controlled with topical therapies, or when those therapies are not advisable. In September 2017, it was also approved in Europe by EMA as a systemic first-line treatment for adults suffering from AD \[[@CR9]\]. Dupilumab is supplied in a single-dose pre-filled syringe and is administered by subcutaneous injection into the thigh, abdomen, or upper arm. The recommended dosage is a loading dose of 600 mg (two 300-mg injections at different sites) followed by 300 mg every other week, with rotation of the injection site. Dupilumab can be used with or without concomitant topical corticosteroids (TCS) \[[@CR15]\]. It has also showed efficacy in patients with persistent asthma and elevated eosinophils, where it improved lung function, reduced exacerbations, and decreased Th2 biomarkers \[[@CR16]\]. Randomized, double-blind, placebo-controlled trials involving adults who had moderate-to-severe AD were performed to check the applicability of dupilumab in the treatment of adults with moderate-to-severe AD. The first two clinical trials, SOLO 1 (NCT02277743) and SOLO 2 (NCT02277769), investigated the safety and efficacy of the dupilumab dosage regimen compared with placebo \[[@CR17]\]. Patients were randomly assigned in a 1:1:1 ratio to receive weekly (qw) subcutaneous injections of dupilumab (300 mg) or placebo or the same dose of dupilumab every other week (q2w) alternating with placebo for 16 weeks. Significantly, more of the patients receiving dupilumab showed an improvement of at least 75% in the Eczema Area and Severity Index (EASI) score compared to the placebo group. The percentages of the patients who reached EASI-50 and EASI-90 as well as the improvement in the Scoring Atopic Dermatitis (SCORAD) and the decrease in the affected body surface area were all significantly higher in the dupilumab groups than in the placebo group (Table [1](#Tab1){ref-type="table"}). A further phase III trial, LIBERTY AD CHRONOS, aimed to analyze the long-term management of moderate-to-severe AD with dupilumab and concomitant topical corticosteroids \[[@CR18]\] (Table [1](#Tab1){ref-type="table"}). At week 52, more of the patients who received dupilumab plus topical corticosteroids achieved the co-primary endpoints of IGA 0/1 and EASI-75 compared to the other two groups (Table [1](#Tab1){ref-type="table"}). The efficacy of dupilumab has been demonstrated in adult patients with a history of inadequate response to/intolerance of CsA \[[@CR19]\]. In the LIBERTY AD CAFÉ trial, 390 patients with an inadequate response to/intolerance of CsA or for whom CsA treatment was medically inadvisable were screened \[[@CR19]\]. The proportion of the patients achieving EASI-75 at week 16 was significantly higher in the dupilumab qw + TCS and q2w + TCS groups compared to placebo + TCS. In all of the clinical studies performed in this field to date, dupilumab has shown a favorable safety profile with no dose-limiting toxicity and few adverse effects. The most common adverse events (AEs) associated with dupilumab are injection-site reactions, which mainly consist of transient erythema or edema. Conjunctivitis seems the only specific side effect, and this can be treated successfully with fluorometholone 0.1% eye drops or tacrolimus 0.03% eye ointment \[[@CR20]\]. The reason why dupilumab causes conjunctivitis is not fully understood, and is currently being evaluated in ophthalmological subtrials. It was hypothesized that blockage of IL-4 and IL-13 would increase the activities of specific ligands involved in atopic keratoconjunctivitis, such as the OX40 ligand \[[@CR21]\]. Generally, the severity of dupilumab-induced conjunctivitis in the majority (\> 90%) of patients is only mild or moderate, and it resolves easily. Actually, there is only one case of bilateral conjunctivitis with consequent cicatricial ectropion associated with dupilumab therapy for AD in the literature \[[@CR22]\].Table 1The main features of clinical trials regarding biologic drugs for moderate-to-severe atopic dermatitisDrug \[ref.\]Trial phase and no. of patients enrolledDosage and durationResultsDupilumab\
\[[@CR17]\]III\
*N* = 671(1) An initial dose of 600 mg dupilumab (two 300 mg injections) on day 1, followed by 300 mg once every 2 weeks (q2w); (2) an initial dose of 600 mg dupilumab on day 1 followed by 300 mg once weekly (qw); or (3) matching placebo\
Duration: 16 weeksThe percentage of patients who had a score of 0 or 1 (clear or almost clear) in the Investigator Global Assessment (IGA) at 16 weeks was 38% in the group that received dupilumab every other week, 37% in the dupilumab weekly group, and 10% in the placebo group (*P* \< 0.0001)\
A reduction of 75% or more in EASI score was more common for the 300-mg dupilumab group (q2w and qw) with respect to placebo (51.3% and 52.5% vs 14.7, *P* \< 0.0001)\
Mean SCORAD percentages were 57.7 ± 2.7 in the dupilumab w2q arm and 29.0 ± 3.21 for placebo (*P* \< 0.001)\
Change from baseline pruritus NRS score at week 16: − 51.0, − 48.9, and − 26.1 in the q2w, qw, and placebo groups, respectivelyDupilumab\
\[[@CR17]\]III\
*N* = 701(1) An initial dose of 600 mg dupilumab (two 300 mg injections) on day 1, followed by 300 mg once every 2 weeks (q2w); (2) an initial dose of 600 mg dupilumab on day 1, followed by 300 mg once weekly (qw); or (3) matching placebo\
Duration: 16 weeksThe percentage of patients that had a score of 0 or 1 (clear or almost clear) in the Investigator Global Assessment (IGA) at 16 weeks was 36.1% in the group that received dupilumab every other week, 36.4% in the dupilumab weekly group, and 8.5% in the placebo group (*P* \< 0.0001)\
A reduction of 75% or more in EASI score was more common for the 300-mg dupilumab group (q2w and qw) with respect to placebo (44.2% and 48.1% vs 11.9, *P* \< 0.0001)\
Mean SCORAD percentages were 51.1 ± 2.02 in the dupilumab w2q arm and 19.7 ± 2.52 for placebo (*p *\< 0.001)\
Change from baseline pruritus NRS score at week 16: − 44.3, − 48.3, and − 15.4 in the q2w, qw, and placebo groups, respectivelyDupilumab \[[@CR18]\]III\
*N* = 740Patients were randomly assigned (3:1:3) to dupilumab 300 mg weekly, dupilumab 300 mg every 2 weeks, or placebo weekly; all patients used concomitant topical corticosteroids (TCS)\
Duration: 52 weeksThe percentage of patients that had a score of 0 or 1 in the Investigator Global Assessment (IGA) was 36.0% in the group that received dupilumab w2q + TCS, 40.0% in dupilumab wq + TCS, and 13% in the placebo group (*P* \< 0.0001)\
A reduction of 75% or more in EASI score was more common for the 300-mg dupilumab + TCS group (q2w and qw) with respect to placebo (65% and 64% vs 22, *P* \< 0.0001)Dupilumab \[[@CR19]\]III\
*N* = 390Patients with inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable, were randomized 1:1:1 to subcutaneous dupilumab 300 mg weekly (qw) or every 2 weeks (q2w) or placebo; all patients used concomitant topical corticosteroids (TCS)\
Duration: 16 weeksProportion of patients achieving EASI-75 at week 16 was significantly higher in the dupilumab qw + TCS and q2w + TCS groups compared to placebo + TCS (59.1% and 62.6% vs 29.6%, respectively; *P* \< 0.001)\
Proportions of patients who achieved an improvement (reduction) of ≥ 4 points from baseline to week 16 in the q2w, qw, and placebo groups were, respectively, 45.7, 40.4, and 14.3% (*P* \< 0.001)\
Proportions of patients with IGA of 0 or 1 and a reduction from baseline of ≥ 2 points at week 16 in the q2w, qw, and placebo groups were, respectively, 40.2, 39.1, and 15% (*P* \< 0.001).\
Mean DLQI changes from baseline at week 16 in the q2w, qw, and placebo groups were, respectively, − 9.5, − 8.8, and − 4.5 (*P* \< 0.001)Fezakinumab \[[@CR31]\]II\
*N* = 60600 mg iv at baseline, followed by 300 mg every 2 weeks or placebo\
Duration: 10 weeks and follow up until 20 weeksMean SCORAD reductions were 13.8 ± 2.7 in the fezakinumab arm and 8.0 ± 3.1 for placebo (*P* = 0.134)\
Body surface area reductions: 12.4% ± 2.4 vs 6.2% ± 2.7 in fezakizumab and placebo, respectively (*P* = 0.009)\
Investigator Global Assessment decline: 0.7 ± 0.2 vs 0.3 ± 0.1 (*P* = 0.034)Lebrikizumab \[[@CR29]\]II\
*N* = 209125 mg single dose, 250 mg single dose, 125 mg every 4 weeks or placebo\
Duration: 12 weeksEASI-50 was reached in 82.4% of patients with lebrikizumab 125 mg every 4 weeks and 62.3% in the placebo group (*P* = 0.026)\
Patients receiving a single dose of lebrikizumab showed no statistically significant improvement in EASI-50 compared with placeboNemolizumab \[[@CR35]\]II\
*N* = 2640.1, 0.5, or 2.0 mg/kg (subcutaneous) or placebo every 4 weeks or an exploratory dose of 2.0 mg/kg every 8 weeks\
Duration: 12 weeksChanges in the pruritus visual-analogue scale were − 43.7% in the 0.1 mg group, − 59.8% in the 0.5 mg group, and − 63.1% in the 2.0 mg group versus − 20.9% in the placebo group (*P* \< 0.01)\
EASI reductions: − 23.0, − 42.3, and − 40.9%, respectively, in the nemolizumab groups versus − 26.6% in the placebo group\
Changes in body-surface area affected by atopic dermatitis were − 7.5, − 20.0, and − 19.4% with nemolizumab versus − 15.7% with placeboNemolizumab \[[@CR36]\]II\
*N* = 1910.1, 0.5, or 2.0 mg/kg sc every 4 or 8 weeks\
Duration: 52 weeksChange from baseline in pruritus visual analog scale score at week 64: − 73.0, − 89.6, − 74.7, and − 79.1 in the 0.1, 0.5, and 2.0-mg/kg q4w and 2.0-mg/kg q8w groups, respectively\
EASI reductions: − 68.5, − 75.8, − 78.9, and − 69.3 in the 0.1-, 0.5-, and 2.0-mg/kg q4w and 2.0-mg/kg q8w groups, respectivelyTralokinumab \[[@CR25]\]II\
*N* = 20445, 150, or 300 mg of subcutaneous tralokinumab or placebo every 2 weeks\
Duration: 12 weeks300 mg of tralokinumab significantly improved the change from baseline EASI score versus placebo (adjusted mean difference, − 4.94; 95% CI − 8.76 to − 1.13; *P* = 0.01)\
A greater percentage of the subjects treated with 300 mg achieved an Investigator Global Assessment response with respect to placebo (26.7% vs 11.8%, *P* = 0.06)\
A reduction of 50% or more in EASI score was more common for the 300-mg tralokinumab group with respect to placebo (73.4% vs 51.9%, *P* = 0.03)\
The percentage of participants with a reduction of 75% or more in EASI score was higher in the 300 mg tralokinumab group (42.5%) than in the placebo group (15.5%, *P* = 0.003)

As with all therapeutic proteins, dupilumab has the potential for immunogenicity. Anti-drug antibodies were developed by approximately 7% of patients with AD who received dupilumab 300 mg every 2 weeks for 16 weeks in SOLO 1 and 2 \[[@CR23]\]. Approximately 30% of patients with anti-drug antibodies (2% overall) had neutralizing antibodies. Similarly, approximately 7% of the patients who received dupilumab 300 mg once every 2 weeks (plus TCS) for 52 weeks in CHRONOS developed antibodies to dupilumab, with approximately 14% of those patients (1% overall) having neutralizing antibodies.

Several ongoing studies involving both children and adolescents will show if these subgroups of the AD population experience equally positive effects, expanding the treatment indication for dupilumab even further \[[@CR24]\].

*Tralokinumab* is a human monoclonal antibody (mAb) that specifically neutralizes IL-13 \[[@CR25]\]. IL-13 is a pleiotropic Th2 cytokine that has been implicated in the pathogenesis of AD, as it impairs skin barrier function by downregulating filaggrin \[[@CR26], [@CR27]\]. IL-13 is increased in both lesional and nonlesional skin of AD subjects, and correlates with disease severity \[[@CR28]\]. A randomized, placebo-controlled, double-blind, clinical phase II study involving 204 adult patients with moderate-to-severe AD was performed \[[@CR25]\]. At week 12, a dose of 300 mg of tralokinumab every 2 weeks resulted in a significant improvement in AD compared with placebo (Table [1](#Tab1){ref-type="table"}). Indeed, the drug significantly improved the EASI change from baseline versus placebo (*P* = 0.01; Table [1](#Tab1){ref-type="table"}). In particular, a greater percentage of the 300 mg tralokinumab-treated participants achieved EASI-50 versus placebo at week 12 (73.4% vs 51.9%,*P* = 0.03) as well as EASI-75 (42.5% vs 15.5%, *P* = 0.003), although concomitant TCS use may constitute a confounding factor that could explain the high placebo efficacy. Interestingly, patients with higher concentrations of biomarkers of increased IL-13 levels showed a better response to tralokinumab. The most frequent AEs in all groups were upper respiratory tract infections, nasopharyngitis, and headache \[[@CR25]\]. All of these data indicated that tralokinumab treatment was associated with early improvements in AD symptoms and an acceptable safety and tolerability profile.

*Lebrikizumab* is a humanized monoclonal antibody that specifically targets IL-13 \[[@CR29]\]. A phase II randomized, double-blind, prospective, placebo-controlled, multicenter study has been performed in adult subjects with moderate-to-severe AD \[[@CR30]\]. In total, 209 patients were randomized (1:1:1:1) to lebrikizumab 125 mg single dose, lebrikizumab 250 mg single dose, lebrikizumab 125 mg every 4 weeks for 12 weeks, or placebo every 4 weeks for 12 weeks. At week 12, EASI-50 was more commonly achieved in patients receiving lebrikizumab 125 mg every 4 weeks than in placebo patients every 4 weeks (82.4% vs 62.3%, *P* = 0.026). The high placebo performance may due to the background of daily TCS application (Table [1](#Tab1){ref-type="table"}). Lebrikizumab was well tolerated; adverse events were similar between groups (66.7% all lebrikizumab vs 66.0% placebo) and were mostly mild or moderate; no AE dose--response relationships were found for the drug. In that study, the efficacy of lebrikizumab 125 mg every 4 weeks led to a significant improvement in patients with moderate-to-severe AD.

IL-22 Inhibitor {#Sec5}
---------------

IL-22 was found to be increased in both acute and chronic AD lesions, correlating with AD severity \[[@CR28]\]. It is produced primarily by Th22 cells and is able to impair epithelial barrier function through its effect on keratinocytes \[[@CR31]\].

*Fezakinumab* is a fully human monoclonal antibody directed against IL-22. A recent randomized, double-blind, placebo-controlled trial with intravenous fezakinumab monotherapy every 2 weeks for 10 weeks and follow-up assessments until 20 weeks has been completed \[[@CR32]\]. Sixty-seven adult AD patients were assessed for eligibility, and 60 patients were randomized 2:1 to fezakinumab (*n* = 40) or placebo (*n* = 20). Results showed that the SCORAD improvement was significantly greater with fezakinumab versus placebo in patients with severe AD at 12 weeks (36.4% vs 22.3%, *P* \< 0.05) and 20 weeks (46.2% vs 22.6%, *P* \< 0.01), while patients with moderate AD seemed to be less responsive to treatment (Table [1](#Tab1){ref-type="table"}) \[[@CR31]\]. AEs occurred with similar frequencies in the fezakinumab and placebo groups \[[@CR32]\]. Taken together, these data showed that fezakinumab was well tolerated, with sustained clinical improvements after the last drug dosing.

IL-31 Receptor Inhibitor {#Sec6}
------------------------

It is already known that the skin expression of IL-31 and IL-31R is increased in patients with AD \[[@CR33]\]. Moreover, AD subjects also show higher serum levels of IL-31 as well as IL-31-producing lymphocytes \[[@CR34]\]. In addition, both serum and skin IL-31 levels have been shown to correlate with AD severity \[[@CR33], [@CR34]\], indicating an important role for IL-31 in AD pathogenesis apart from itch pathophysiology \[[@CR35]\].

*Nemolizumab* is a monoclonal antibody directed against IL-31 receptor A \[[@CR33]\]. A phase II, randomized, double-blind, placebo-controlled, 12-week trial involving 264 adult patients with moderate-to-severe AD has been recently completed \[[@CR36]\]. Patients received subcutaneous nemolizumab (at doses of 0.1, 0.5, or 2.0 mg/kg of body weight) or placebo every 4 weeks. Significant reductions in pruritus were seen from baseline to week 12 in all arms receiving nemolizumab every 4 weeks; the result was statistically significant with respect to placebo in all drug groups (Table [1](#Tab1){ref-type="table"}). EASI score changes were significantly higher for 0.5 and 2 mg nemolizumab with respect to placebo (Table [1](#Tab1){ref-type="table"}). AD exacerbation, nasopharyngitis, upper respiratory tract infection, peripheral edema, and increased creatine kinase levels were the most common AEs registered. In particular, exacerbation of AD and peripheral edema were more common in the nemolizumab groups than in the placebo group.

More recently, the long-term efficacy and safety of nemolizumab injected subcutaneously every 4 weeks (q4w) or 8 weeks (q8w) were evaluated in a phase II, 52-week, double-blind extension trial \[[@CR37]\]. Patients (*n* = 191) continued the previous nemolizumab dose (0.1, 0.5, or 2.0 mg/kg q4w or 2.0 mg/kg q8w) \[[@CR36]\]. An improvement from baseline in the pruritus visual analog scale score was maintained/increased from weeks 12 to 64, with the greatest improvement seen for the 0.5-mg/kg q4w group (Table [1](#Tab1){ref-type="table"}). The EASI improvement was also maintained/increased to week 64, with the highest results observed with a dosage of 2.0 mg/kg q4w (Table [1](#Tab1){ref-type="table"}), showing that nemolizumab for up to 64 weeks was efficacious and well tolerated overall in patients with moderate-to-severe AD inadequately controlled by topical therapy. The most common AEs in patients treated over the long term with nemolizumab (≥ 5% of patients were randomized to nemolizumab throughout the study period) were nasopharyngitis (27%), exacerbation of AD (25%), increased blood creatine phosphokinase (11%), upper respiratory tract infection (9%), headache (8%), peripheral edema (6%), and impetigo (6%).

Conclusion {#Sec7}
==========

The frequency of AD is increasing all over the world, especially in industrialized countries and urbanized areas. The frequency of this disease in adults also seems to be increasing, although it is probably underdiagnosed. Due to its chronicity and subjective symptoms, the disease greatly impacts on the quality of life of the patients. Currently, only few systemic immunosuppressive drugs are available for moderate-to-severe forms, and CsA is the only licensed drug for the treatment. Moreover, the important side effects of immune suppressors limit their use. Therefore, having more secure and effective medicines would be desirable. Over the last few years, increased knowledge about AD pathogenesis has made it possible to develop new therapeutic agents capable of blocking individual mediators of inflammation. Some monoclonal antibodies against specific cytokines (IL-4, IL-13, IL-22, IL-31) have been developed. Data obtained from the trials regarding efficacy and safety are encouraging for most of the agents. Dupilumab (anti-IL-4/IL-13) is the only biologic agent approved for AD in some countries. In conclusion, biologic therapies will probably markedly change the natural history of AD. Indeed, they will hopefully be able to increase the disease-free periods and decrease the number of exacerbations, thus improving the quality of life of AD patients.
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